Invasive fungal infections are emerging as increasing problems in children with cancer and with AIDS. The Mycology Unit of the Infectious Diseases Section of the Pediatric Oncology Branch develops new approaches to diagnosis, treatment, and prevention of invasive fungal infections in immunocompromised children through a multi disciplinary program of combined laboratory and clinical research. By rapidly translating new laboratory developments into clinical trials, our program provides cutting edge modalities for treating and preventing infections due to Candida, Aspergillus, and important emerging fungal pathogens in children with cancer or AIDS. In order to improve the treatment and prevention of these infections, the Pediatric Oncology Branch is currently investigating several novel types of antifungal compounds, including cyclodextrin-itraconazole for refractory oral candidiasis in children with AIDS and lipid formulations of amphotericin B for serious deep infections in immunocompromised children.

Supportive Care Protocols

Thomas J.Walsh, M.D., Immunocompromised Host Section

Stephen J. Chanock, M.D., Immunocompromised Host Section

Last Updated: September 20, 2005

NCI Home Page|| NIH Home Page

© 2002-2003, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute